Drug Class Description
DNA-reactive cytotoxics (antineoplastic agents).

Generic Name
Mitoxantrone [mitozantrone]

Drug Description
Solution in vials.

Presentation
Injection, mitoxantrone hydrochloride 2 mg/mL.

Indications
Treatment of advanced breast cancer, non-Hodgkin's lymphoma, and adult acute non-lymphocytic leukaemia. Novantrone has also been used in the palliation of non-resectable hepatocellular carcinoma.

Child Dosage
Not recommended.

Contra Indications
Not for intrathecal use. Demonstrated hypersensitivity to the drug. Pregnancy - patients and their partners should be advised to avoid conception for at least six months after cessation of therapy. Lactation - discontinue breastfeeding before starting treatment.

Special Precautions
Should be used only by clinicians Should be used only by clinicians familiar with the use of antineoplastic agents, and having the facilities for regular monitoring of clinical, haematological and biochemical parameters during and after treatment.

Adverse Reactions
Leucopenia. Thrombocytopenia and anaemia. Nausea, vomiting and alopecia. Blue-green colouration of urine. Blue discolouration of the skin and nails reported occasionally.

Manufacturer
Wyeth

Drug Availability
(POM)

Updated
02 June 2009